1 A Pharma GmbH

DUBLIN--( BUSINESS WIRE )--The "Huntington's Disease Market Analysis by Treatment (Disease-modifying Therapies, Symptomatic Treatment) and by Region - Global Forecast to 2029" report has been added to ResearchAndMarkets.com's offering. The Hutington's Disease market size is estimated to be USD 475.3 million in 2021 and is expected to witness a CAGR of 21.61% during the forecast period 2022-2029. Ingrezza's expected label expansion for treating chorea associated with Huntington's disease, the high prevalence of HD in Western countries, and a robust product pipeline of disease-modifying treatments is expected to drive the market. However, low success rate in clinical trials is expected to restrain the market growth. Segmentation: Hutington's Disease Market Report 2021-2029 By Treatment (Revenue, USD Million) Disease-modifying Therapies Symptomatic Treatment By Region (Revenue, USD Million) North America U.S Canada Europe Germany France UK Spain Italy Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of APAC Latin America Brazil Mexico Argentina Rest of LATAM Middle East & Africa South Africa GCC Rest of MEA Companies Mentioned Teva (Israel) Novartis AG (Switzerland) GSK (UK) AbbVie (US) Merck (US) Boehringer Ingelheim (Germany) Impax Laboratories (US) Lundbeck (Denmark) UCB (Belgium) Valeant Pharmaceuticals (Canada) Acadia (US) Sun Pharma (India) Wockhardt (India) Dr. Reddy's (India) Intas (India) US WorldMeds (US) Zydus Cadila (India) Cipla (India) Strides (India) 1 A Pharma (India) Upsher-Smith (US) For more information about this report visit https://www.researchandmarkets.com/r/aboj38